Currently, there are 48.73M common shares owned by the public and among those 47.17M shares have been available to trade.
The company’s stock has a 5-day price change of 45.95% and 63.64% over the past three months. CRDF shares are trading 155.41% year to date (YTD), with the 12-month market performance up to 190.77% higher. It has a 12-month low price of $1.25 and touched a high of $6.42 over the same period. CRDF has an average intraday trading volume of 740.66K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 43.18%, 33.79%, and 20.08% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Cardiff Oncology Inc (NASDAQ: CRDF) shares accounts for 24.93% of the company’s 48.73M shares outstanding.
It has a market capitalization of $193.29M and a beta (3y monthly) value of 1.91. The earnings-per-share (ttm) stands at -$0.95. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.95% over the week and 8.71% over the month.
Earnings per share for the fiscal year are expected to decrease by -7.10%, and 1.41% over the next financial year.
Looking at the support for the CRDF, a number of firms have released research notes about the stock. Craig Hallum stated their Buy rating for the stock in a research note on September 06, 2024, with the firm’s price target at $8. Robert W. Baird was of a view on December 08, 2021 that the stock is Outperform, while Maxim Group gave the stock Buy rating on August 09, 2021, issuing a price target of $30- $20. H.C. Wainwright on their part issued Buy rating on October 22, 2020.
